REFERENCES

[1] WHO, Global Vaccine Market Report.Geneva, Switzerland: World Health

Organization, 2019, [Online]. Available: https://apps.who.int/iris/handle/10665/

311278

[2] EMA, Guideline on Quality, Non-Clinical and Clinical Requirements for

Investigational Advanced Therapy Medicinal Products in Clinical Trials. London,

United Kingdom: European Medicines Agency, 2019.

[3] W. F. Kaemmerer, “How will the field of gene therapy survive its success?,” (in

eng), Bioeng. Transl. Med., vol. 3, no. 2, pp. 166–177, 2018.

[4] A. Offersgaard et al., “SARS-CoV-2 production in a scalable high cell density

bioreactor,” Vaccines, vol. 9, no. 7, p. 706, 2021.

[5] A. Nikolay, A. Léon, K. Schwamborn, Y. Genzel, and U. Reichl, “Process in-

tensification of EB66® cell cultivations leads to high-yield yellow fever and Zika

virus production,” Appl. Microbiol. Biotechnol., vol. 102, no. 20, pp. 8725–8737,

2018.

[6] A. F. Pihl et al., “High density Huh7.5 cell hollow fiber bioreactor culture for high-

yield production of hepatitis C virus and studies of antivirals,” Sci. Rep., vol. 8,

no. 1, p. 17505, 2018.

[7] N. Nayerossadat, T. Maedeh, and P. A. Ali, “Viral and nonviral delivery systems for

gene delivery,” (in eng), Adv. Biomed. Res., vol. 1, p. 27, 2012.

[8] D. Radhakrishnan, E. A. Wells, and A. S. Robinson, “Strategies to enhance pro-

ductivity and modify product quality in therapeutic proteins,” Curr. Opin. Chem.

Eng., vol. 22, pp. 81–88, 2018.

[9] B. Kalbfuss, A. Knöchlein, T. Kröber, and U. Reichl, “Monitoring influenza virus

content in vaccine production: Precise assays for the quantitation of hemaggluti-

nation and neuraminidase activity,” Biologicals, vol. 36, no. 3, pp. 145–161, 2008.

[10] Y. Genzel, J. Rödig, E. Rapp, and U. Reichl, “Vaccine Production: Upstream

Processing with Adherent or Suspension Cell Lines,” in Animal Cell Biotechnology:

Methods and Protocols, R. Pörtner, Ed. Totowa, NJ: Humana Press, 2014, pp. 371–393.

[11] A. Nikolay, T. Bissinger, G. Granicher, Y. Wu, Y. Genzel, and U. Reichl,

“Perfusion control for high cell density cultivation and viral vaccine production,”

Methods Mol. Bio.l, vol. 2095, pp. 141–168, 2020.

[12] L. Pelz et al., “Semi-continuous propagation of influenza A virus and its defective

interfering particles: analyzing the dynamic competition to select candidates for

antiviral therapy,” (in eng), J. Virol., vol. 95, p. e01174-21, Sep. 2021.

[13] R. J. Hill, “An evaluation of a method of quantitative radial immunodiffusion,” (in

eng), Immunochemistry, vol. 5, no. 2, pp. 185–202, Mar. 1968.

[14] J. M. Wood, G. C. Schild, R. W. Newman, and V. Seagroatt, “An improved single-

radial-immunodiffusion technique for the assay of influenza haemagglutinin an-

tigen: application for potency determinations of inactivated whole virus and subunit

vaccines,” (in eng), J. Biol. Stand., vol. 5, no. 3, pp. 237–247, 1977.

[15] J. M. Wood and J. P. Weir, “Standardisation of inactivated influenza vaccines-

Learning from history,” (in eng), Influenza Other Respir. Viruses, vol. 12, no. 2,

pp. 195–201, Mar. 2018.

[16] F. Tapia, T. Laske, M. A. Wasik, M. Rammhold, Y. Genzel, and U. Reichl,

“Production of defective interfering particles of influenza A virus in parallel con-

tinuous cultures at two residence times—Insights from qPCR measurements and

viral dynamics modeling,” (in English), Front. Bioeng. Biotechnol. vol. 7, Article

no. 275, 2019.

[17] R. Pörtner, Bioreactors for Mammalian cells, vol. 9, 2015. ISBN 978-3-319-

10319-8.

Process intensification

167